hMSH3 overexpression and cellular response to cytotoxic anticancer agents

Rita Pepponi, Grazia Graziani, Sabrina Falcinelli, Patrizia Vernole, Lauretta Levati, Pedro Miguel Lacal, Elena Pagani, Enzo Bonmassar, Josef Jiricny, Stefania D'Atri

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Mutations or transcriptional silencing of mismatch repair genes have been linked with tumour cell resistance to O6-guanine methylating agents, 6-thioguanine, cisplatin, doxorubicin and etoposide. Recently, it has been demonstrated that overexpression of the MSH3 protein is associated with depletion of the mismatch binding factor MutSα, and then with a marked reduction in the efficiency of base/base mismatch repair. In the present study we evaluated sensitivity of the HL-60 cell line and its methotrexate-resistant subline HL-60R, which overexpresses the hMSH3 gene, to a panel of chemotherapeutic agents. Cell growth inhibition induced by temozolomide, 6-thioguanine and N-methyl-N'-nitro-N-nitrosoguanidine was significantly lower in the hMSH3-overexpressing HL-60R cell line as compared with the HL-60 parental line. Moreover, HL-60R cells were more resistant than HL-60 cells to chromosome aberrations induced by either N-methyl-N'- nitro-N-nitrosoguanidine or temozolomide, and to apoptosis triggered by the latter drug. Both cell lines were equally susceptible to growth inhibition induced by cisplatin, etoposide or doxorubicin. In addition, HL-60 and HL-60R cells showed comparable sensitivity to the clastogenic and apoptotic effects of cisplatin and etoposide. These results further confirm that loss of base/base mismatch repair is the most important molecular mechanism involved in cell resistance to O6-guanine methylating agents and 6-thioguanine. However, the status of the mismatch repair system could still influence tumour cell sensitivity to cisplatin, etoposide and doxorubicin, depending on the specific component of the system that is lost, and on the genetic background of the cell.

Original languageEnglish
Pages (from-to)1131-1137
Number of pages7
JournalCarcinogenesis
Volume22
Issue number8
Publication statusPublished - 2001

Fingerprint

Cytotoxins
Antineoplastic Agents
DNA Mismatch Repair
temozolomide
Etoposide
Thioguanine
Cisplatin
HL-60 Cells
Doxorubicin
Methylnitronitrosoguanidine
Guanine
Cell Line
Growth
Methotrexate
Chromosome Aberrations
Genes
Neoplasms
Apoptosis
Mutation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Pepponi, R., Graziani, G., Falcinelli, S., Vernole, P., Levati, L., Lacal, P. M., ... D'Atri, S. (2001). hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis, 22(8), 1131-1137.

hMSH3 overexpression and cellular response to cytotoxic anticancer agents. / Pepponi, Rita; Graziani, Grazia; Falcinelli, Sabrina; Vernole, Patrizia; Levati, Lauretta; Lacal, Pedro Miguel; Pagani, Elena; Bonmassar, Enzo; Jiricny, Josef; D'Atri, Stefania.

In: Carcinogenesis, Vol. 22, No. 8, 2001, p. 1131-1137.

Research output: Contribution to journalArticle

Pepponi, R, Graziani, G, Falcinelli, S, Vernole, P, Levati, L, Lacal, PM, Pagani, E, Bonmassar, E, Jiricny, J & D'Atri, S 2001, 'hMSH3 overexpression and cellular response to cytotoxic anticancer agents', Carcinogenesis, vol. 22, no. 8, pp. 1131-1137.
Pepponi R, Graziani G, Falcinelli S, Vernole P, Levati L, Lacal PM et al. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis. 2001;22(8):1131-1137.
Pepponi, Rita ; Graziani, Grazia ; Falcinelli, Sabrina ; Vernole, Patrizia ; Levati, Lauretta ; Lacal, Pedro Miguel ; Pagani, Elena ; Bonmassar, Enzo ; Jiricny, Josef ; D'Atri, Stefania. / hMSH3 overexpression and cellular response to cytotoxic anticancer agents. In: Carcinogenesis. 2001 ; Vol. 22, No. 8. pp. 1131-1137.
@article{d8072b96017848cab37b3857d0b93653,
title = "hMSH3 overexpression and cellular response to cytotoxic anticancer agents",
abstract = "Mutations or transcriptional silencing of mismatch repair genes have been linked with tumour cell resistance to O6-guanine methylating agents, 6-thioguanine, cisplatin, doxorubicin and etoposide. Recently, it has been demonstrated that overexpression of the MSH3 protein is associated with depletion of the mismatch binding factor MutSα, and then with a marked reduction in the efficiency of base/base mismatch repair. In the present study we evaluated sensitivity of the HL-60 cell line and its methotrexate-resistant subline HL-60R, which overexpresses the hMSH3 gene, to a panel of chemotherapeutic agents. Cell growth inhibition induced by temozolomide, 6-thioguanine and N-methyl-N'-nitro-N-nitrosoguanidine was significantly lower in the hMSH3-overexpressing HL-60R cell line as compared with the HL-60 parental line. Moreover, HL-60R cells were more resistant than HL-60 cells to chromosome aberrations induced by either N-methyl-N'- nitro-N-nitrosoguanidine or temozolomide, and to apoptosis triggered by the latter drug. Both cell lines were equally susceptible to growth inhibition induced by cisplatin, etoposide or doxorubicin. In addition, HL-60 and HL-60R cells showed comparable sensitivity to the clastogenic and apoptotic effects of cisplatin and etoposide. These results further confirm that loss of base/base mismatch repair is the most important molecular mechanism involved in cell resistance to O6-guanine methylating agents and 6-thioguanine. However, the status of the mismatch repair system could still influence tumour cell sensitivity to cisplatin, etoposide and doxorubicin, depending on the specific component of the system that is lost, and on the genetic background of the cell.",
author = "Rita Pepponi and Grazia Graziani and Sabrina Falcinelli and Patrizia Vernole and Lauretta Levati and Lacal, {Pedro Miguel} and Elena Pagani and Enzo Bonmassar and Josef Jiricny and Stefania D'Atri",
year = "2001",
language = "English",
volume = "22",
pages = "1131--1137",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - hMSH3 overexpression and cellular response to cytotoxic anticancer agents

AU - Pepponi, Rita

AU - Graziani, Grazia

AU - Falcinelli, Sabrina

AU - Vernole, Patrizia

AU - Levati, Lauretta

AU - Lacal, Pedro Miguel

AU - Pagani, Elena

AU - Bonmassar, Enzo

AU - Jiricny, Josef

AU - D'Atri, Stefania

PY - 2001

Y1 - 2001

N2 - Mutations or transcriptional silencing of mismatch repair genes have been linked with tumour cell resistance to O6-guanine methylating agents, 6-thioguanine, cisplatin, doxorubicin and etoposide. Recently, it has been demonstrated that overexpression of the MSH3 protein is associated with depletion of the mismatch binding factor MutSα, and then with a marked reduction in the efficiency of base/base mismatch repair. In the present study we evaluated sensitivity of the HL-60 cell line and its methotrexate-resistant subline HL-60R, which overexpresses the hMSH3 gene, to a panel of chemotherapeutic agents. Cell growth inhibition induced by temozolomide, 6-thioguanine and N-methyl-N'-nitro-N-nitrosoguanidine was significantly lower in the hMSH3-overexpressing HL-60R cell line as compared with the HL-60 parental line. Moreover, HL-60R cells were more resistant than HL-60 cells to chromosome aberrations induced by either N-methyl-N'- nitro-N-nitrosoguanidine or temozolomide, and to apoptosis triggered by the latter drug. Both cell lines were equally susceptible to growth inhibition induced by cisplatin, etoposide or doxorubicin. In addition, HL-60 and HL-60R cells showed comparable sensitivity to the clastogenic and apoptotic effects of cisplatin and etoposide. These results further confirm that loss of base/base mismatch repair is the most important molecular mechanism involved in cell resistance to O6-guanine methylating agents and 6-thioguanine. However, the status of the mismatch repair system could still influence tumour cell sensitivity to cisplatin, etoposide and doxorubicin, depending on the specific component of the system that is lost, and on the genetic background of the cell.

AB - Mutations or transcriptional silencing of mismatch repair genes have been linked with tumour cell resistance to O6-guanine methylating agents, 6-thioguanine, cisplatin, doxorubicin and etoposide. Recently, it has been demonstrated that overexpression of the MSH3 protein is associated with depletion of the mismatch binding factor MutSα, and then with a marked reduction in the efficiency of base/base mismatch repair. In the present study we evaluated sensitivity of the HL-60 cell line and its methotrexate-resistant subline HL-60R, which overexpresses the hMSH3 gene, to a panel of chemotherapeutic agents. Cell growth inhibition induced by temozolomide, 6-thioguanine and N-methyl-N'-nitro-N-nitrosoguanidine was significantly lower in the hMSH3-overexpressing HL-60R cell line as compared with the HL-60 parental line. Moreover, HL-60R cells were more resistant than HL-60 cells to chromosome aberrations induced by either N-methyl-N'- nitro-N-nitrosoguanidine or temozolomide, and to apoptosis triggered by the latter drug. Both cell lines were equally susceptible to growth inhibition induced by cisplatin, etoposide or doxorubicin. In addition, HL-60 and HL-60R cells showed comparable sensitivity to the clastogenic and apoptotic effects of cisplatin and etoposide. These results further confirm that loss of base/base mismatch repair is the most important molecular mechanism involved in cell resistance to O6-guanine methylating agents and 6-thioguanine. However, the status of the mismatch repair system could still influence tumour cell sensitivity to cisplatin, etoposide and doxorubicin, depending on the specific component of the system that is lost, and on the genetic background of the cell.

UR - http://www.scopus.com/inward/record.url?scp=0034903747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903747&partnerID=8YFLogxK

M3 - Article

C2 - 11470740

AN - SCOPUS:0034903747

VL - 22

SP - 1131

EP - 1137

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 8

ER -